CVS Caremark Reaches New 52-Week High (CVS)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- CVS Caremark (NYSE: CVS) hit a new 52-week high Wednesday as it is currently trading at $59, above its previous 52-week high of $58.50 with 562,447 shares traded as of 9:35 a.m. ET. Average volume has been 5.8 million shares over the past 30 days.

CVS Caremark has a market cap of $71.32 billion and is part of the services sector and retail industry. Shares are up 20.4% year to date as of the close of trading on Tuesday.

CVS Caremark Corporation, together with its subsidiaries, provides integrated pharmacy health care services in the United States. The company has a P/E ratio of 19, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates CVS Caremark as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company shows low profit margins. You can view the full CVS Caremark Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

This Is How to Avoid Becoming Amazon Roadkill

Cramer: Dominoes Are in Play Today

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)

Cramer: How to Avoid Being Amazon Roadkill